Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection | Heckels and Williams Genome Medicine 2010 2 43 http content 2 7 43 w Genome Medicine REVIEW L_ The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection John E Heckels and Jeannette N Williams Abstract There is a particular need for an effective vaccine against life-threatening meningitis and septicemia caused by Neisseria meningitidis meningococcus serogroup B strains. Vaccine strategies incorporating capsular polysaccharide have proved effective against other meningococcal serogroups but are not applicable to serogroup B. Attention has therefore focused on the subcapsular outer membrane protein antigens as potential vaccine components. The sequencing of genomes from three serogroups and the availability of the corresponding translated protein databases combined with the development of sensitive proteomic techniques have opened up new avenues of meningococcal vaccine research. This has resulted in the identification of potential candidate antigens for incorporation into multicomponent meningococcal vaccines. Background The development of an effective vaccine against all strains of Neisseria meningitidis meningococcus the major cause of life-threatening bacterial meningitis and septicemia is a priority for infectious disease research. Meningococci can be classified into serogroups based on the structure of their extracellular capsular polysaccharide with serogroups B and C being traditionally responsible for the majority of invasive disease in most temperate countries and serogroup A causing epidemic infections in sub-Saharan Africa. Correspondence jeh@ Molecular Microbiology Group Sir Henry Wellcome Laboratories Division of Infection Inflammation and Immunity University of Southampton Faculty of Medicine Mailpoint 814 Southampton General Hospital Southampton SO16 6YD UK Contributed equally 2 BioMed Central 2010 BioMed Central Ltd The first generation of vaccines contained .
